The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants

British Journal of Haematology
Loes E VisserBruno H Ch Stricker

Abstract

Heart failure has been identified as a risk factor for increased coumarin anticoagulant responsiveness in several small-scale experiments. Epidemiological studies quantifying the risk of overanticoagulation by heart failure in a non-selected population on coumarins are scarce. Therefore, we investigated whether patients with heart failure have an increased risk of overanticoagulation and determined the effect of incidental heart failure on coumarin dose requirements. A cohort study of all patients was performed from an outpatient anticoagulation clinic treated with acenocoumarol or phenprocoumon between 1 January 1990 and 1 January 2000. All cohort members were followed until the first occurrence of an international normalized ratio (INR) > or = 6.0, the last INR assessment, death, loss to follow-up, or end of the study period. Of the 1077 patients in the cohort, 396 developed an INR > or = 6.0. The risk of overanticoagulation was 1.66 [95% confidence interval (CI): 1.33-2.07] for cases of prevalent heart failure and 1.91 (95%CI: 1.31-2.79) for incidental cases. The decrease in dose requirements in patients with incidental heart failure showed a significant trend from the fifth INR measurement preceding the date of incidental h...Continue Reading

References

Mar 1, 1977·Clinical Pharmacokinetics·K Bachmann, R Shapiro
Jul 1, 1991·European Journal of Epidemiology·A HofmanF A van den Ouweland
Aug 1, 1980·Canadian Journal of Physiology and Pharmacology·B D BhagatJ I Pina
Jul 6, 1995·The New England Journal of Medicine·S C CannegieterE Briët
Jun 3, 1998·British Journal of Haematology
Aug 9, 2001·European Heart Journal·W J RemmeUNKNOWN Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology
Oct 1, 1952·The American Journal of the Medical Sciences·D F COVERT
Sep 1, 1949·The American Journal of the Medical Sciences·D STATS, S DAVISON

❮ Previous
Next ❯

Citations

Apr 17, 2013·Molecular Diagnosis & Therapy·C F SamerJ A Desmeules
Dec 7, 2013·Langenbeck's Archives of Surgery·Martin HoffmannErik Schloericke
Oct 24, 2007·European Journal of Epidemiology·Albert HofmanJacqueline C M Witteman
Aug 31, 2011·European Journal of Epidemiology·Albert HofmanJacqueline C M Witteman
Sep 4, 2009·European Journal of Epidemiology·Albert HofmanJacqueline C M Witteman
Oct 1, 2011·Expert Opinion on Drug Safety·Heather D EdwardsSusan E Conway
Dec 24, 2015·Current Medical Research and Opinion·Timothy H SelfAmanda Howard-Thompson
May 1, 2012·Revista Portuguesa De Cardiologia : Orgão Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology·João Morais
Jul 18, 2006·Thrombosis Research·Carl van WalravenAlan J Forster
Mar 19, 2013·Journal of the American College of Cardiology·Mark D HuffmanDonald M Lloyd-Jones
Apr 22, 2011·Journal of Pharmacy Practice·Pamela J White
Apr 1, 2014·The Cochrane Database of Systematic Reviews·Gregory Y H Lip, Eduard Shantsila
Dec 25, 2009·Circulation. Cardiovascular Quality and Outcomes·Adam J RoseElaine M Hylek
Jan 14, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Toni L Ripley, Edith Nutescu
May 26, 2020·Expert Review of Cardiovascular Therapy·Paul L den ExterMenno V Huisman
Sep 12, 2015·Journal of Cardiovascular Pharmacology·Sameh Alzubiedi, Mohammad I Saleh
May 19, 2021·The Cochrane Database of Systematic Reviews·Eduard ShantsilaGregory Yh Lip

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.